Global Respiratory Drugs Detail Industrial and Market studies to 2022 - Pipeline and Detail Industrial and Market studies Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

"Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.

Get Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=811827

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in CF, where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The COPD and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.

However, over the past decade the treatment of respiratory disorders has developed significantly, as has the importance for novel therapies and targeted therapies. The approval of the products Orkambi and Kalydeco, in 2014 and 2012 respectively, gave patients disease-modifying treatment options for CF. Another important entry was the first biologic drug - omalizumab - approved in 2014 for the treatment of severe asthma. The trend of developing targeted therapies continued with the approval of the maintenance treatment Nucala (mepolizumab) in November 2015.

Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area. Overall, 908 products are currently in active in development for respiratory disorders.

** Scope
– The respiratory disorders market is characterized by entrenched, commercially successful therapies. 
Which classes of drug dominate the market?
What additional benefits have newly approved therapies brought to the market? 
What are the future prospects for the leading brands?

– The pipeline contains a range of molecule types and molecular targets, with a growing presence of targeted therapies.
Which molecular targets appear most frequently in the pipeline?
What are the commercial prospects for the most promising late-stage pipeline products?

– Respiratory disorders clinical trials have an overall attrition rate of 89.1%.
What are the failure rates at individual phases of clinical development?
How do the key respiratory disorders compare in terms of clinical trial failure rate?

– The respiratory disorders market is forecast to rise from a value of $28.1 billion in 2015 to $46.6 billion in 2022, at a CAGR of 7.5%.
How much of a role will pipeline product approvals play in market growth?
Are the large number of recently approved products expected to drive market growth?
Will generic competition have a significant impact on the market over the forecast period?
Which products face generic competition?

– Big pharma holds a notable presence in the market.
What are the leading companies in terms of market share?
Which companies are forecast to experience the greatest growth in market share? 
Which company will hold the largest market share in 2022?
How dependent are the key companies on this disease cluster for revenue?
Which companies rely heavily on this disease cluster for revenue?

** Reasons to buy
This report will allow you to - 
Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment landscape in respiratory disorders.
Assess the current treatment landscape, with product profiles on prominent marketed therapies, including revenue forecasts.
Analyze the respiratory disorders pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from respiratory disorder products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
Identify commercial opportunities in the respiratory disorder deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

– Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7

– 2 Introduction 10
2.1 Therapy Area Introduction 10
2.2 Epidemiology 10
2.2.1 Asthma 11
2.2.2 Chronic Obstructive Pulmonary Fibrosis 12
2.2.3 Idiopathic Pulmonary Fibrosis 13
2.2.4 Cystic Fibrosis 14
2.3 Pathophysiology 15
2.3.1 Asthma 15
2.3.2 Chronic Obstructive Pulmonary Disease 17
2.3.3 Idiopathic Pulmonary Fibrosis 18
2.3.4 Cystic Fibrosis 20
2.4 Symptoms 21
2.5 Diagnosis 22
2.5.1 Asthma 22
2.5.2 Chronic Obstructive Pulmonary Fibrosis 22
2.5.3 Idiopathic Pulmonary Fibrosis 23
2.5.4 Cystic Fibrosis 24
2.6 Disease Severity and Prognosis 24
2.6.1 Asthma 24
2.6.2 Chronic Obstructive Pulmonary Fibrosis 27
2.6.3 Idiopathic Pulmonary Fibrosis 29
2.6.4 Cystic Fibrosis 30
2.7 Treatment 32
2.7.1 Asthma 32
2.7.2 Chronic Obstructive Pulmonary Fibrosis 33
2.7.3 Idiopathic Pulmonary Fibrosis 33
2.7.4 Cystic Fibrosis 34

3 Key Marketed Products 36
3.1 Overview 36
3.2 Advair - GSK 37
3.3 Spiriva - Boehringer Ingelheim, Pfizer 39
3.4 Symbicort - AstraZeneca/Astellas 41
3.5 Singulair (montelukast) - Merck & Co. 43
3.6 Flixotide/Flovent - GSK 45
3.7 Ventolin - GSK 47
3.8 Kalydeco - Vertex 48
3.9 Pulmozyme - Roche 50
3.10 Esbriet - Roche 51
3.11 TOBI - Novartis 53
3.12 Conclusion 54

4 Pipeline Landscape Assessment 56
4.1 Overview 56
4.2 Pipeline Development Landscape 56
4.3 Molecular Targets in the Pipeline 59
4.4 Clinical Trials 61
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 61
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 65
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 68
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 71
4.4.5 Conclusion 74

5 Multi-scenario Market Forecast to 2022 75
5.1 Overall Market Size 75
5.2 Generic Penetration 76
5.3 Revenue Forecast by Molecular Target 79
5.3.1 G-Protein Coupled Receptors 79
5.3.2 Immune/Inflammatory Mediators 80
5.3.3 Transcription Factors 81
5.3.4 Signal Transduction 82
5.3.5 CFTR Modulator 83
5.4 Assessment of Key Pipeline Products 84
5.4.1 Dupilumab - Regeneron Pharmaceuticals/Sanofi 84
5.4.2 Benralizumab - AstraZeneca/Medimmune 85
5.4.3 Lebrikizumab - Roche/Genentech 87
5.4.4 PT010 (Budesonide plus Formoterol Fumarate plus Glycopyrronium) - AstraZeneca/Pearl Therapeutics 88
5.4.5 Tralokinumab - AstraZeneca 89
5.4.6 Batefenterol - GSK/Theravance 90
5.4.7 Conclusion 91

6 Company Analysis and Positioning 92
6.1 Revenue and Market Share Analysis by Company 93
6.1.1 GlaxoSmithKline 97
6.1.2 Vertex 98
6.1.3 AstraZeneca 99
6.1.4 Roche 101
6.1.5 Novartis 102
6.1.6 Boehringer Ingelheim 103
6.2 Company Landscape 104
6.3 Marketed and Pipeline Portfolio Analysis 105

7 Strategic Consolidations 109
7.1 Licensing Deals 109
7.1.1 Deal by Region, Year and Value 109
7.1.2 Deals by Stage of Development and Value 111
7.1.3 Deals by Molecule Type and Molecular Target 112
7.1.4 Table for Licensing Deals Valued Above $100m 114
7.2 Co-development Deals 117
7.2.1 Deals by Region, Year and Value 117
7.2.2 Deals by Stage of Development and Value 118
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 119
7.2.4 Table for Co-development Deals Valued Above $100m 121

8 Appendix 123
8.1 Bibliography 123
8.2 All Pipeline Drugs by Phase 130
8.2.1 Discovery 130
8.2.2 Preclinical 139
8.2.3 IND/CTA filed/Phase 0 171
8.2.4 Phase I 172
8.2.5 Phase II 181
8.2.6 Phase III 191
8.2.7 Pre-registration 197
8.3 Abbreviations 199
8.4 Methodology 200
8.4.1 Coverage 200
8.4.2 Secondary Research 200
8.4.3 Market Size and Revenue Forecasts 201
8.4.4 Pipeline Analysis 201
8.4.5 Competitive Landscape 201
8.5 Contact Us 202
8.6 Disclaimer 202

– List of Table
Table 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology, 2016 11
Table 2: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 0-4 Years of Age 25
Table 3: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 5-11 Years of Age 26
Table 4: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Youths of 12 Years or More and Adults 27
Table 5: Respiratory Disorders Therapeutics Market, Global, COPD Disease Severity, 2016 28
Table 6: Respiratory Disorders Therapeutics Market, Global, COPD Patient Risk Categories, 2016 29
Table 7: Respiratory Disorders Therapeutics Market, Global, IPF Severity Classification, 2016 29
Table 8: Respiratory Disorders Therapeutics Market, Global, CF Severity Classification, 2016 31
Table 9: Respiratory Disorders Therapeutics Market, Global, COPD Treatment Algorithm, 2016 33

Full Report @ http://www.researchmoz.us/global-respiratory-drugs-market-to-2022-pipeline-and-market-characterized-by-growing-prominence-of-targeted-therapies-with-asthma-and-cystic-fibrosis-leading-the-way-report.html

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Researchmoz Global Pvt. Ltd.
90 State Street,
Albany, NY 12207,
United States,
Tel: 866-997-4948 (Us-Canada Toll Free),
Tel: +1-518-621-2074

This release was published on openPR.